The Economist: Saving the children
“…The coming year will see the widespread testing of the first effective vaccine against Plasmodium falciparum, the parasite that causes the most deadly type of malaria. The vaccine, called RTS,S, will be given exclusively to children. It has been under development since 2001 by a collaboration between Glaxo SmithKline, a British drug company, and PATH, an American global-health charity. … Although the deployment of RTS,S in 2018 — in Ghana, Kenya, and Malawi — will only be a pilot scheme intended to test the vaccine’s effectiveness in the rough and tumble of African clinical life, it will be a big one…” (Carr, December 2017).